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Summary
Background The Harmonising Outcome Measures for Eczema (HOME) initiative has
established a core outcome set of domains for atopic eczema (AE) clinical trials.
Previous consensus meetings have agreed on preferred instruments for clinician-
reported signs (Eczema Area and Severity Index, EASI) and patient-reported
symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consen-
sus decisions from the HOME VII meeting.
Objectives To complete the core outcome set for AE by agreeing on core outcome
instruments for the domains of quality of life (QoL), long-term control and itch
intensity.
Methods A face-to-face consensus meeting was held in Tokyo, Japan (8–10 April
2019) including 75 participants (49 healthcare professionals/methodologists, 14
patients, 12 industry representatives) from 16 countries. Consensus decisions
were made by presentations of evidence, followed by whole and small group dis-
cussions and anonymous voting using predefined consensus rules.
Results It was agreed by consensus that QoL should be measured using the Derma-
tology Life Quality Index (DLQI) for adults, the Children’s Dermatology Life Qual-
ity Index (CDLQI) for children and the Infant’s Dermatology Quality of Life Index
(IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP)
instrument or the Atopic Dermatitis Control Test (ADCT) should be used.
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Consensus was not reached over the frequency of data collection for long-term con-
trol. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as
an additional instrument for the symptom domain in trials of older children and
adults. Agreement was reached that all core outcome instruments should be cap-
tured at baseline and at the time of primary outcome assessment as a minimum.
Conclusions For now, the core outcome set for clinical trials in AE is complete. The
specified domains and instruments should be used in all new clinical trials and
systematic reviews of eczema treatments.
What is already known about this topic?
• Core outcomes sets improve the design and reporting of clinical trials, reduce selective
outcome reporting bias and facilitate meta-analysis of results in systematic reviews.
• The HOME core outcome set for eczema recommends the inclusion of four core
domains in all atopic eczema trials: clinician-reported signs, patient-reported symp-
toms, health-related quality of life (HrQoL) and long-term control.
• Clinician-reported signs should be captured using the Eczema Area and Severity
Index (EASI) and patient-reported symptoms using the Patient-Oriented Eczema
Measure (POEM).
What does this study add?
• The HOME core outcome set is now complete and recommended core outcome
instruments have been agreed on for all four domains.
• Core outcome instruments for HrQoL: Dermatology Life Quality Index (DLQI) for
adults, Children’s Dermatology Life Quality Index (CDLQI) for children and
Infant’s Dermatology Quality of Life Index (IDQoL) for infants.
• Core outcome instruments for long-term control: either the Recap of Atopic
Eczema (RECAP) or the Atopic Dermatitis Control Test (ADCT).
• In addition, itch intensity should be measured using the peak NRS-11 past 24 h
for trials including older children and adults.
What are the clinical implications of this work?
• If all future trials of eczema treatments include the HOME core outcome instruments,
then trial results will be more readily incorporated into meta-analyses in systematic
reviews and clinical care will be informed by the best available evidence.
Core outcome sets are considered an essential factor for pro-
gressing evidence-based medicine by permitting studies to be
compared and combined in a meaningful way in future sys-
tematic reviews and meta-analyses.1 Core outcome sets also
ensure the inclusion and reporting of valid endpoints that are
meaningful to patients. The Harmonising Outcomes Measures
for Eczema (HOME) initiative has proposed four core domains
to be captured in all clinical trials of atopic eczema (AE, syn.
atopic dermatitis, eczema) treatments: clinician-reported signs,
patient-reported symptoms, health-related quality of life
(HrQoL) and long-term control.2 The outcome measurement
instruments recommended for capturing signs and symptoms
are the Eczema Area and Severity Index (EASI) and Patient-
Oriented Eczema Measure (POEM), respectively.2–4
HrQoL has been discussed at HOME consensus meetings
previously, for adults (HOME IV) and children (HOME V),5,6
but consensus had not been reached over the preferred instru-
ments to recommend for the core outcome set.
The domain of long-term control was the main topic of dis-
cussion at the HOME V meeting in Nantes in 2017, where it
was agreed that long-term control should be captured by a
combination of repeated measurement of existing core
domains (signs, symptoms and HrQoL), plus a patient global
assessment of control. It was recommended that these aspects
should be measured repeatedly during trials wherever possi-
ble, and that further research was required to agree on a pre-
ferred instrument for capturing eczema control, as well as the
optimum frequency and timing of assessments.6
For the symptoms domain, itch intensity had been pro-
posed previously as an important addition to the POEM instru-
ment, which captures frequency of symptoms including itch,
but does not quantify itch severity.5
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Achieving consensus over the preferred instruments to com-
plete the HOME core outcome set for AE trials was the focus of
discussions at a 3-day consensus meeting held in Tokyo, Japan
(8–10 April 2019) – HOME VII. This report outlines a summary
of the consensus recommendations from the HOME VII meeting.
Methods
Organization of consensus meeting and consensus rules
Methods used to select outcome instruments for inclusion in
the core outcome set were guided by the HOME methodologi-
cal Roadmap7 and internationally agreed guidance for selecting
outcome instruments.8 The latter recommends four key stages
to the selection of core outcome instruments: conceptual con-
siderations, identification of existing instruments, quality assess-
ment of instruments, and generic aspects (e.g. minimum
criteria for inclusion should be content validity, internal consis-
tency if relevant and feasibility). Decisions during the meeting
were informed by up-to-date systematic reviews of validation
studies for relevant outcome measurement instruments.
Seventy-five delegates attended the meeting, plus five
observers/translators including 43 (57%) healthcare profes-
sionals, 14 (19%) patients/representatives, six (8%) method-
ologists and 12 (16%) industry representatives (Table S1; see
Supporting Information). The meeting included a mixture of
presentations, whole and small group discussions, and anony-
mous voting using electronic keypads.
Discussions focused on establishing agreement over: (i) pre-
ferred instruments for measuring HrQoL in adults and children;
(ii) long-term control in adults and children; and (iii) itch
intensity in adults (as a proposed additional instrument to cap-
ture an essential missing element of the symptoms domain). In
addition, discussion of the recommended frequency of data col-
lection and timing of assessments was debated.
Small group discussions were used to evaluate content valid-
ity and feasibility, using summary cards as prompts to generate
discussion and to rank instrument options. Anonymized elec-
tronic voting was employed to reach consensus decisions. As
with previous HOME meetings, consensus was reached on a
statement when fewer than 30% of voters disagreed. Individuals
involved in the development of specific instruments were
excluded from the vote to avoid conflicts of interest.
Full details of the methods used are provided in the pub-
lished meeting report.
Results
Quality of Life domain
Domain definition
Quality of life is a complex, often multidimensional construct
that is usually measured by multi-item questionnaires. At the
HOME IV meeting, the HOME initiative voted that psychologi-
cal functioning, social functioning and physical functioning
are essential subdomains for the construct QoL and that there
are no other essential subdomains.5 Available instruments for
AE differ according to age group: different instruments exist
for infants, children and adults. There is not one QoL instru-
ment for AE that can be used across all ages.
Evidence provided at the meeting
An updated systematic review of the measurement proper-
ties of QoL outcome measures for infants, children and
adults with AE was presented.9 According to this system-
atic review, none of the existing patient-reported outcome
measures for QoL could be recommended for use. In addi-
tion, a newly developed short-form of the Childhood Ato-
pic Dermatitis Impact Scale (CADIS) was presented.10 This
scale showed excellent internal consistency, test–retest
reliability, construct validity and responsiveness and was
considered to be a more feasible scale than the original
45-item CADIS.11
Small group discussions and feedback
Content validity is recommended as a primary consideration
when selecting a core outcome instrument.8 Small group dis-
cussions therefore focused on rating the content validity of
each of nine candidate QoL instruments.12 Each group con-
sisted of a mixture of clinicians, patients, industry representa-
tives and methodologists, and discussions were guided by a
facilitator (a member of the HOME executive committee).
Each group discussed either one or two instruments. The
COnsensus-based Standards for the selection of health Mea-
surement INstruments (COSMIN) criteria13 on relevance, com-
prehensiveness and comprehensibility were used to determine
the overall content validity rating per instrument. The facilita-
tor of each group presented their findings and final ratings in
plenary (Table 1).
Consensus vote
Whether an instrument could be recommended as the core
outcome instrument for QoL was voted on for each age
group. Seventy-two attendees took part in the consensus vot-
ing (five conflicted attendees abstained). The Infant’s Dermati-
tis Quality of Life Index (IDQoL) was voted as the
recommended instrument for infants [8 of 70 (11%) dis-
agreed] and the Children’s Dermatology Life Quality Index
(CDLQI) for children [6 of 69 (9%) disagreed]. For adults,
both the Dermatology Life Quality Index (DLQI) and Skindex
were voted as potentially suitable candidate instruments for
the core set [9 of 72 (13%) and 16 of 70 (23%) disagreed,
respectively], but following further discussion and a second
consensus vote, the DLQI was chosen as the preferred instru-
ment for adults [11 of 72 (15%) disagreed].
In conclusion, the family of instruments, IDQoL, CDLQI
and DLQI, which are the most frequently used instruments in
the literature, were recommended as the core outcome instru-
ments for the QoL domain in AE clinical trials.
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Long-term control domain
Domain definition
A conceptual model for the construct of ‘long-term control’
was presented and debated (Figure 1, reproduced with per-
mission).14 This model was based on mixed-methods research
and stakeholder opinion to define the construct of eczema
control.6,15–17
The HOME domain of ‘long-term control’ was clarified as
being ‘eczema control’ measured repeatedly over time. This
domain is relevant to adults and children with eczema, and to
people with all severities of disease.
Instruments considered
In preparation for the meeting, five possible outcome mea-
surement instruments to capture ‘patient-reported eczema
control’ were identified. Four were multi-item instruments
[Atopic Dermatitis Control Test (ADCT),18 Recap of Atopic
Eczema (RECAP),14 Patient Benefit Index (PBIv20)19–21 and
Atopic Dermatitis Score 7 (ADS7)22] and one was a single-



















(proxy- and self-reported) InToDermQoL DLQI Skindex-16 ABS-A
Content
validity rating
+ + +  – –   –
IDQoL, Infant’s Dermatitis Quality of Life Index; CDLQI, Children’s Dermatology Life Quality Index; CADIS, Childhood Atopic Dermatitis
Impact Scale; DISABKIDS, the European DISABKIDS Group questionnaire; InToDermQoL, Infants and Toddlers Dermatology Quality of Life;
DLQI, Dermatology Life Quality Index; ABS-A, Atopic Dermatitis Burden Scale for Adults; +, sufficient; –, insufficient; , inconsistent
Figure 1 Conceptual framework for eczema control (reproduced with permission from Howells et al.14).
142 Recommended core outcome instruments in AE trials: results of HOME VII, Thomas et al.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021) 185, pp139–146
item global eczema severity instrument Patient Global Assess-
ment (PtGA).23,24 The ADCT and RECAP instruments were
specifically developed to measure ‘eczema control’, PBI is a
measure of patient-related benefit following dermatology
treatment (but is not eczema-specific) and ADS7 assesses
eczema symptoms and burden of disease. These instruments
were identified through a systematic review of the literature
and via a survey of the HOME membership to identify newly
developed and unpublished instruments.
Quality assessment of the instruments was conducted prior to
the meeting according to COSMIN methodology.13 Content valid-
ity for capturing eczema control was insufficient for the ADS7
instrument and so this instrument was not considered further. All
instruments were felt to be feasible to include in the core outcome
set. Three instruments (ADCT, RECAP and PtGA) had evidence of
‘sufficient’ content validity, PBI had ‘inconsistent’ evidence of
content validity (manuscript in preparation).
During the consensus meeting, individual instruments were
discussed and ranked in six small groups with a variety of stake-
holders in each group. The results of these small group discus-
sions are shown in Table 2. The majority of groups preferred a
single-item ‘global eczema control’ instrument, but five of the six
groups felt that the existing validated PtGA instrument was not
suitable for this purpose as the response options of mild, moder-
ate or severe disease were not seen as being appropriate to the
construct being measured, and there was no clear option. It was
also noted that the domain measured by the PtGA was disease
severity and not disease ‘control’, per se. Development and valida-
tion of a single-item global eczema control instrument is therefore
required. All groups agreed that the PBI instrument was not suit-
able as an ‘eczema control’ measure because it asks about needs
and benefits of treatment rather than ‘eczema control’ and so was
rapidly rejected by most groups. Of the remaining two multi-item
control instruments, both RECAP and ADCT were judged to be of
high quality and similar in content, making it difficult to choose
one over the other.
Consensus voting
Following whole group discussion and indicative voting, 54
attendees took part in the consensus voting (12 conflicted
attendees abstained). ADCT and RECAP were both voted as
potential candidate instruments for the core outcome set [15
of 54 (278%) and 16 of 54 (296%), respectively, disagreed
with their inclusion].
It was also recommended that further research should be
conducted to develop a single-item global control instrument
that could be evaluated at future HOME meetings.
As ADCT and RECAP were both newly developed (and very
similar) instruments, with limited validation data to inform a
choice between the two, it was agreed that both should be
recommended for use as core outcome instruments to measure
long-term control for the time being [12 of 53 (23%) dis-
agreed].
No consensus was reached over the preferred frequency of
data collection for the domain of long-term control. This will
be discussed at future HOME meetings.
Itch intensity (additional symptom instrument)
Domain definition
Itch intensity was defined as intensity measured by a single-
item instrument, such as a numerical rating scale (NRS), ver-
bal rating scale (VRS) or visual analogue scale (VAS), mea-
sured over a specific period of time, e.g. the past 24 h or past
week. This subdomain is relevant to adults and children with
eczema, with all severities of disease.
Instruments considered
Evidence was presented on outcome measurement instruments
of itch intensity regarding instrument properties and quality
of the evidence on measurement properties. Instruments were
identified through two systematic reviews25,26 and an addi-
tional search update. Further, a pre-meeting survey of the
HOME membership (106 respondents: 50 clinicians, 33
patients or patient representatives, 14 industry representatives,
seven methodologists, two not stated) identified the prefer-
ences over response options (NRS, VRS, VAS), type of inten-
sity (peak itch, average itch) and recall period (past 24 h, past
week) of itch intensity instruments (Table 3).
A systematic review of measurement properties for patient-
reported outcome measures of itch intensity included 23
Table 2 Summary of small group feedback on long-term control outcome instruments
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Single-item / multi-item preferred 50/50 split N/A Single Single Single Multi
Single-item instruments
Existing validated PtGA suitable? No No No No Yes No
Development / validation of a new single-item instrument required? Yes Yes Yes Yes Yes Yes
Multi-item instruments
1st-choice instrument RECAP RECAP RECAP RECAP N/A RECAP
2nd-choice instrument ADCT ADCT ADCT ADCT N/A ADCT
PBIv20 and ADS7 NP NP NP NP NP NP
ADCT, Atopic Dermatitis Control Test instrument; ADS7, Atopic Dermatitis Score 7; PBI, Patient Benefit Index; PtGA, Patient Global Assess-
ment instrument; RECAP, Recap of eczema control instrument; N/A, not applicable or not ranked; NP, not preferred
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studies on 23 instruments (search 1965–2015).25 Preliminary
results of an update to this review were presented at the
HOME meeting and included 14 extra studies, resulting in a
total number of 32 instruments for consideration (search
2015–2019) (publication in preparation). In addition, the sys-
tematic review of measurement properties of eczema symp-
toms, including itch intensity, was presented (search 1965–
2015).26 Eighteen instruments were included. An update
revealed only one new paper in eczema concerning itch inten-
sity.27
Based on the quality assessment of the instruments and
studies using COSMIN methodology, the following single-item
instruments were considered: (i) investigated in patients with
itch: NRS-6 (recall period not specified), peak NRS-11 past 24
h, verbal NRS (VNRS)-4 (recall period variable), VAS (hori-
zontal) (recall period variable)25 and (ii) investigated in adult
patients with eczema: VAS (horizontal) past 24 h,28 VRS-5
past 24 h28 and NRS-11 past 24 h.27
Only three instruments were validated for eczema in adults,
and only for the recall period of the past 24 h. The VAS and
VRS past 24 h28 had limited evidence for construct validity.
The peak NRS-11 past 24 h27 has been validated for several
measurement properties (i.e. content validity, test–retest relia-
bility, discriminating/known groups validity, sensitivity to
change, construct validity). This study indicated that peak itch
was easier to remember and to rate compared with average
itch; also, peak interpretation was more precise and consistent.
Consensus voting
After whole group discussions, 63 attendees took part in the
consensus voting. Only five of 63 (8%) disagreed with the
statement that itch intensity should be included in the symp-
toms domain and reported in addition to POEM. All industry
representatives refrained from the remainder of the voting due
to perceived or potential conflicts of interest with the instru-
ments. It was agreed that peak itch should be measured rather
than average itch; only three of 50 (6%) disagreed with
including peak itch, whereas 34 of 50 (68%) disagreed with
including average itch. The recall period ‘past 24 hours’ for
capturing peak itch intensity was preferred with only four of
50 (8%) disagreeing with this timescale compared with more
than half disagreeing with using the recall period ‘past week’
(28 of 50, 56%).
Consensus was reached to include the peak NRS-11 past 24
h27 as the core outcome instrument for measuring the subdo-
main of itch intensity in adults [4 of 48 (8%) disagreed]. In
this instrument, peak itch is measured by the following ques-
tion: ‘On a scale of 0 to 10, with 0 being “no itch” and 10
being “worst itch imaginable”, how would you rate your itch
at the worst moment during the previous 24 hours?’27
This recommendation was made only for adults, as there
was no validation data available for younger people. However,
the group suggested using the instrument for anyone who can
self-report. It is not considered appropriate as a proxy mea-
sure.
In the future, further validation data on NRS-11, including
in younger people, will be investigated.
Frequency of data collection
Discussion over the optimal timing and frequency of data col-
lection for the core outcome instruments was held. Discus-
sions were informed by a pre-meeting survey, which scoped
the views of the wider HOME membership over the preferred
timing and frequency of data collection for the core outcome
set instruments.
It was agreed by consensus that core outcomes should be
collected, as a minimum, at baseline and at the time of the
primary outcome assessment, which is usually equivalent to
end of treatment in trials [none of 72 (0%) disagreed]. No
agreement was reached as to the preferred timing of outcome
assessments at other timepoints but it was agreed that recom-
mendations (not mandatory) on timepoints for the core out-
comes set should be made as part of future HOME activities
[nine of 72 (13%) disagreed].
Discussion
During this 3-day HOME consensus meeting, agreement was
reached over the preferred instruments for capturing HrQoL,
long-term control and itch intensity. It was also agreed that
outcomes should be recorded as a minimum at baseline and at
the time of the primary outcome assessment. These recom-
mendations build on the previously agreed core outcome rec-
ommendations and completes the HOME core outcome set for
AE.
For HrQoL, the preferred core outcome instruments are
IDQoL, CDLQI and DLQI for infants, children and adults,
Table 3 Results of pre-meeting survey of HOME membership
regarding itch preferences
Would you prefer response options using:
Numerical rating scale (NRS) 50 (47%)
Verbal rating scale (VRS) 22 (21%)
Visual analogue scale (VAS) 24 (23%)
Unsure 7 (7%)
Not stated 3 (3%)
Would you prefer itch intensity to be measured using:
Average itch 45 (425%)
Peak itch 45 (425%)
Unsure 9 (8%)
Not stated 7 (7%)
Which of the following timescales do you consider to be the most appropriate for
capturing itch intensity?
Past 24 h 41 (39%)
Past week 48 (45%)
None of these 9 (8%)
Not stated 8 (75%)
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respectively.29–31 This recommendation is welcomed as the
inclusion of HrQoL assessment in clinical trials has been lim-
ited by lack of recommended outcome instruments.
For long-term control, the RECAP and ADCT outcome
instruments14,32 are recommended and for the symptoms
domain it is recommended that itch intensity be collected for
adults and older children using a 0–10 NRS instrument of
peak itch in the last 24 h, in addition to POEM.
Future research and consensus discussions are required to
evaluate new QoL instruments as they become available, to
explore the use of Patient-Reported Outcomes Measurement
Information System (PROMIS) instruments33 for assessing dif-
ferent aspects of QoL, to develop and validate a single-item
global assessment of eczema control, to further validate the
RECAP and ADCT instruments and to establish the optimum
frequency and timing of outcome assessments to facilitate
meta-analysis of trial findings.
In considering strengths and limitations, these consensus
decisions were conducted over 3 days during a face-to-face
meeting led by an Independent Chair who had 20+ years of
experience of developing core outcomes sets (M.B.). Decisions
were made based on the best available evidence, including the
results of systematic reviews, surveys of the HOME member-
ship, and international online patient discussion groups con-
ducted prior to the consensus meeting. Our methods were
informed by guidance from Outcome Measures in Rheumatol-
ogy (OMERACT),34 COMET,35 COSMIN8 and the HOME
Roadmap.7
Because patients and patient representatives represented just
19% of attendees at the meeting, it is possible that some felt
it difficult to express their thoughts during the meeting. We
strengthened the patient voice by holding a separate session
for patients prior to the main meeting and by using small
group consensus methods to inform decisions, thus enabling
patients to engage more fully. We also had translators working
with patients attending the meeting who were unable to speak
English.
In conclusion, for now, the core outcome set for clinical
trials in AE is complete and the specified outcome domains
and outcome measurement instruments should be used in all
new clinical trials and systematic reviews of AE treatments.
Ongoing efforts are required to ensure global uptake of the
agreed core outcome instruments. Regulatory authorities, jour-
nal editors and funders can play a key role in supporting
implementation.
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